

Aerocrine

Press release
20 March, 2008

Aerocrine files patent infringement suit against Medisoft in Germany

SOLNA, Sweden – 20 March, 2008 – Aerocrine AB (OMX Nordic Exchange: AERO) today announced the filing with the District Court of Dusseldorf of a Complaint and Motion to prevent Medisoft, P.A.E from marketing and selling its exhaled Nitric Oxide (NO) analyser in Germany. The claim seeks both an injunction and damages.

Medisoft P.A.E. is a Belgian company that recently began marketing and selling the Hypair exhaled NO analyser in Germany. Aerocrine claims the Medisoft Hypair Analyser infringes four of Aerocrine's European patents. They are EP Nos. 0,606,351; 0,724,623; 1,439,781; and 1,545,305.

"Aerocrine's view is that Medisoft's product Hypair uses Aerocrine's proprietary technology", says Paul de Potocki, CEO of Aerocrine AB. "We welcome other companies to join Aerocrine in bringing the benefits of inflammation monitoring to patients and care providers, but we will defend our company's patents resolutely".

For more information, contact:

Paul de Potocki, CEO, telephone: +46 8 629 07 82

About Aerocrine

Aerocrine AB is a medical technology company focused on the improved management and care of patients with inflammatory airway diseases. As the pioneer and leader in the technology to monitor and manage airway inflammation, Aerocrine markets NIOX® Flex and NIOX MINO®. Both products enable fast and reliable management of airway inflammation and may therefore play a critical role in more effective diagnosis, treatment and follow-up of patients with inflammatory airway diseases such as asthma. Aerocrine is based in Sweden with subsidiaries in the US, Germany and the UK. Aerocrine shares were listed on the Stockholm Stock Exchange on 15 June, 2007.

Aerocrine may be required to disclose the information provided herein pursuant to the Securities Markets Act. The information was submitted for publication at 2.00 pm on March the 20 th 2008.
--